A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)
Condition: Lymphoma, Large B-Cell, Diffuse Interventions: Biological: Zilovertamab Vedotin; Drug: Cyclophosphamide; Drug: Doxorubicin; Biological: Rituximab; Biological: Rituximab Biosimilar; Drug: Prednisone; Drug: Prednisolone Sponsor: Merck Sharp & Dohme LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials